NCT01881425

Brief Summary

Assess the safety and effectiveness of the InnFocus MicroShunt when used to lower intraocular pressure (IOP) in subjects with primary open angle glaucoma where the IOP is not controlled when using maximum tolerated glaucoma medications.

Trial Health

93
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
732

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Dec 2015

Longer than P75 for not_applicable

Geographic Reach
6 countries

29 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 17, 2013

Completed
2 days until next milestone

First Posted

Study publicly available on registry

June 19, 2013

Completed
2.5 years until next milestone

Study Start

First participant enrolled

December 15, 2015

Completed
4.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 15, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 15, 2020

Completed
2.8 years until next milestone

Results Posted

Study results publicly available

October 26, 2022

Completed
Last Updated

October 26, 2022

Status Verified

October 1, 2022

Enrollment Period

4.1 years

First QC Date

June 17, 2013

Results QC Date

July 11, 2022

Last Update Submit

October 25, 2022

Conditions

Keywords

POAG

Outcome Measures

Primary Outcomes (2)

  • Number of Participants With > 20% Decrease in Mean Diurnal Intraocular Pressure

    The primary effectiveness outcome is ≥ 20% reduction in mean diurnal IOP without increasing number of glaucoma medications from baseline to 12 months follow-up

    12 months

  • Number of Participants With > 20% Decrease in Diurnal Intraocular Pressure

    The primary effectiveness outcome is ≥ 20% reduction in mean diurnal IOP without increasing number of glaucoma medications from baseline to 24 months follow-up

    24 months

Secondary Outcomes (4)

  • Mean Diurnal Intraocular Pressure Change

    12 months

  • Mean Diurnal Intraocular Pressure Change

    24 months

  • Number of Participants With Postoperative Interventions at 12 Months

    12 months

  • Participants With Postoperative Interventions at 24 Months

    24 months

Study Arms (2)

InnFocus MicroShunt

EXPERIMENTAL

InnFocus MicroShunt

Device: InnFocus MicroShunt

Trabeculectomy

ACTIVE COMPARATOR

glaucoma surgery to reduce IOP

Procedure: Glaucoma Surgery

Interventions

An initial pocket is created under the conjunctiva and Tenon's capsule and the wound bed is treated for two minutes with mitomycin C (MMC, 0.2 mg/ml)soaked sponges. This is done using a "fornix-based" conjunctival incision at the corneoscleral junction. A partial thickness scleral flap with its base at the corneoscleral junction after cauterization of the flap area, and a window opening is created under the flap with a Kelly-punch to remove a portion of the sclera, Schlemm's canal and the trabecular meshwork to enter the anterior chamber. An iridectomy is done in many cases to prevent future blockage of the sclerostomy. The scleral flap is then sutured loosely back in place with several sutures. The conjunctiva is closed in a watertight fashion at the end of the procedure.

Trabeculectomy

An initial pocket is created under the conjunctiva and Tenon's capsule and the wound bed is treated for two minutes with mitomycin C (MMC, 0.2 mg/ml)soaked sponges. This is done using a "fornix-based" conjunctival incision at the corneoscleral junction. After cauterization of the flap area, a knife is used to create a shallow pocket at the scleral surface and an opening into the AC. The device is then threaded through the track until the proximal end is in the anterior chamber and the fin of the device is pushed into the shallow scleral pocket. The device is checked to observe aqueous flow and the distal end placed under the Tenons/conjunctiva. The conjunctiva is closed in a watertight fashion at the end of the procedure.

InnFocus MicroShunt

Eligibility Criteria

Age40 Years - 85 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (29)

Eye Physicians and Surgeons of Arizona

Glendale, Arizona, 85306, United States

Location

Arizona Eye Consultants

Tucson, Arizona, 85710, United States

Location

Vold Vision

Fayetteville, Arkansas, 72704, United States

Location

University of California at Davis Eye Center

Davis, California, 95817, United States

Location

UCLA Jules Stein Eye Institute

Los Angeles, California, 90095, United States

Location

Ophthalmic Consultants of Connecticut

Fairfield, Connecticut, 06824, United States

Location

Inter-Mountain Eye Care

Eagle, Idaho, 83616, United States

Location

Chicago Glaucoma Consultants and CGC Eye Center

Glenview, Illinois, 60026, United States

Location

Eugene and Marilyn Glick Eye Institute

Indianapolis, Indiana, 46290, United States

Location

Stiles Eyecare Excellence

Overland Park, Kansas, 66213, United States

Location

Washington Eye Physicians and Surgeons

Chevy Chase, Maryland, 20815, United States

Location

Minnesota Eye Consultants, PA

Bloomington, Minnesota, 55431, United States

Location

Midwest Eye Surgery Center

Omaha, Nebraska, 68131, United States

Location

New York Eye and Ear Infirmary of Mt. Sinai

New York, New York, 10003, United States

Location

Glaucoma Consultants of the Capital Region

Slingerlands, New York, 12159, United States

Location

Cincinnati Eye Institute

Cincinnati, Ohio, 45242, United States

Location

Ophthalmic Surgeons and Consultants of Ohio

Columbus, Ohio, 43215, United States

Location

Dean McGee Eye Institute

Oklahoma City, Oklahoma, 73104, United States

Location

Ophthalmic Partners of Pennsylvania

Bala-Cynwyd, Pennsylvania, 19004, United States

Location

Glaucoma Associates of Texas

Dallas, Texas, 75231, United States

Location

Ophthalmology Associates

Fort Worth, Texas, 76102, United States

Location

The Robert Cizik Eye Clinic

Houston, Texas, 77030, United States

Location

Rashid, Rice, Flynn and Reilley Eye Associates

San Antonio, Texas, 78229, United States

Location

Specialty Eye Care

Bellevue, Washington, 98004, United States

Location

Pole Ophtalmologique de la Clinique Mutualiste

Pessac, Bordeaux, 33600, France

Location

Pisa University Hospital Cisanello

Pisa, 56126, Italy

Location

University Eye Clinic Maastricht

Maastricht, 6229 HX, Netherlands

Location

Hospital Clínico San Carlos

Madrid, 28040, Spain

Location

Moorfields Eye Hospital

London, EC1V 2PD, United Kingdom

Location

Related Publications (2)

  • Park J, Rittiphairoj T, Wang X, E JY, Bicket AK. Device-modified trabeculectomy for glaucoma. Cochrane Database Syst Rev. 2023 Mar 13;3(3):CD010472. doi: 10.1002/14651858.CD010472.pub3.

  • Baker ND, Barnebey HS, Moster MR, Stiles MC, Vold SD, Khatana AK, Flowers BE, Grover DS, Strouthidis NG, Panarelli JF; INN005 Study Group. Ab-Externo MicroShunt versus Trabeculectomy in Primary Open-Angle Glaucoma: One-Year Results from a 2-Year Randomized, Multicenter Study. Ophthalmology. 2021 Dec;128(12):1710-1721. doi: 10.1016/j.ophtha.2021.05.023. Epub 2021 May 27.

MeSH Terms

Conditions

Glaucoma, Open-Angle

Condition Hierarchy (Ancestors)

GlaucomaOcular HypertensionEye Diseases

Results Point of Contact

Title
Sharon Herbert, Director of Global Clinical Operations
Organization
InnFocus, Inc. (a Santen Company)

Study Officials

  • Paul Palmberg, M.D., Ph.D.

    Bascom Palmer Eye Institute

    STUDY DIRECTOR

Publication Agreements

PI is Sponsor Employee
No
Restriction Type
OTHER
Restrictive Agreement
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 17, 2013

First Posted

June 19, 2013

Study Start

December 15, 2015

Primary Completion

January 15, 2020

Study Completion

January 15, 2020

Last Updated

October 26, 2022

Results First Posted

October 26, 2022

Record last verified: 2022-10

Locations